Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema

Danny M. Cohn, Nicholas J. Viney, Lauré M. Fijen, Eugene Schneider, Veronica Alexander, Shuting Xia, Gwendolyn E. Kaeser, Charvi Nanavati, Brenda F. Baker, Richard S. Geary,

New England Journal of Medicine · 2020 · 78 citations · 10 references

DOIFull text

Open access

Concepts

Abstract

at a dose of 80 mg every 3 to 4 weeks for 7 to 8 months. Treatment was accompanied by a reduction in the angioedema attack rate. (Funded by Amsterdam UMC.).

References

10